Evidence map›Paper›PMID 36925912›Full record

ArticleFrontiers in oncology2023

Breast cancer subtype and clinical characteristics in women from Peru.

Valentina A Zavala, Sandro Casavilca-Zambrano, Jeannie Navarro-Vásquez, Lizeth I Tamayo, Carlos A Castañeda, Guillermo Valencia, Zaida Morante, Mónica Calderón, Julio E Abugattas, Henry L Gómez and 10 more

Open access · goldFull text read
In one paragraph

Article in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Evaluation of Multiple Breast Cancer Polygenic Risk Score Panels in Women of Latin American Heritage.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2025
    Article
  4. Article
  5. Breast cancer in northern Peru: molecular subtypes and HER2 low.Revista peruana de medicina experimental y salud publica · 2024
    Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 3 institutions in 2 countries.

Valentina A ZavalaDepartment of Public Health Sciences, University of California, Davis, Davis, CA, United States.
Sandro Casavilca-ZambranoInstituto Nacional de Enfermedades Neoplásicas, Departamento de Patología, Lima, Peru.
Jeannie Navarro-VásquezInstituto Nacional de Enfermedades Neoplásicas, Departamento de Investigación, Lima, Peru.
Lizeth I TamayoDepartment of Public Health Sciences, The University of Chicago, Chicago, IL, United States.
Carlos A CastañedaInstituto Nacional de Enfermedades Neoplásicas, Departamento de Oncología Médica, Lima, Peru.
Guillermo ValenciaInstituto Nacional de Enfermedades Neoplásicas, Departamento de Oncología Médica, Lima, Peru.
Zaida MoranteInstituto Nacional de Enfermedades Neoplásicas, Departamento de Oncología Médica, Lima, Peru.
Mónica CalderónInstituto Nacional de Enfermedades Neoplásicas, Departamento de Oncología Médica, Lima, Peru.
Julio E AbugattasInstituto Nacional de Enfermedades Neoplásicas, Departamento de Cirugía de Mamas y tumores Blandos, Lima, Peru.
Henry L GómezInstituto Nacional de Enfermedades Neoplásicas, Departamento de Oncología Médica, Lima, Peru.
Hugo A FuentesInstituto Nacional de Enfermedades Neoplásicas, Departamento de Oncología Médica, Lima, Peru.
Ruddy Liendo-PicoagaInstituto Nacional de Enfermedades Neoplásicas, Banco de Tumores, Lima, Peru.
Jose M CotrinaInstituto Nacional de Enfermedades Neoplásicas, Departamento de Cirugía de Mamas y tumores Blandos, Lima, Peru.
Silvia P NeciosupInstituto Nacional de Enfermedades Neoplásicas, Departamento de Oncología Médica, Lima, Peru.
Katia RoqueInstituto Nacional de Enfermedades Neoplásicas, Departamento de Oncología Médica, Lima, Peru.
Jule VásquezInstituto Nacional de Enfermedades Neoplásicas, Departamento de Oncología Médica, Lima, Peru.
Luis MasInstituto Nacional de Enfermedades Neoplásicas, Departamento de Oncología Médica, Lima, Peru.
Marco Gálvez-NinoInstituto Nacional de Enfermedades Neoplásicas, Departamento de Oncología Médica, Lima, Peru.
Laura FejermanDepartment of Public Health Sciences, University of California, Davis, Davis, CA, United States.
Tatiana VidaurreInstituto Nacional de Enfermedades Neoplásicas, Departamento de Oncología Médica, Lima, Peru.
Instituto Nacional de Enfermedades Neoplásicas · PEUniversity of California, Davis · USUniversity of Chicago · US

Funding

Biological implications of breast cancer protective variants in Latin Americanwomen with high Indigenous American ancestryR01CA204797 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI FEJERMAN, LAURA · 2016 to 2020
$1.9M
NCI NIH HHS R01 CA204797
6 · The paper itself

Abstract

Introduction: Breast cancer is a heterogeneous disease, and the distribution of the different subtypes varies by race/ethnic category in the United States and by country. Established breast cancer-associated factors impact subtype-specific risk; however, these included limited or no representation of Latin American diversity. To address this gap in knowledge, we report a description of demographic, reproductive, and lifestyle breast cancer-associated factors by age at diagnosis and disease subtype for The Peruvian Genetics and Genomics of Breast Cancer (PEGEN-BC) study. Methods: The PEGEN-BC study is a hospital-based breast cancer cohort that includes 1943 patients diagnosed at the Instituto Nacional de Enfermedades Neoplásicas in Lima, Peru. Demographic and reproductive information, as well as lifestyle exposures, were collected with a questionnaire. Clinical data, including tumor Hormone Receptor (HR) status and Human Epidermal Growth Factor Receptor 2 (HER2) status, were abstracted from electronic medical records. Differences in proportions and mean values were tested using Chi-squared and one-way ANOVA tests, respectively. Multinomial logistic regression models were used for multivariate association analyses. Results: The distribution of subtypes was 52% HR+HER2-, 19% HR+HER2+, 16% HR-HER2-, and 13% HR-HER2+. Indigenous American (IA) genetic ancestry was higher, and height was lower among individuals with the HR-HER2+ subtype (80% IA Discussion: The characteristics of the PEGEN-BC study participants do not suggest heterogeneity by tumor subtype except for IA genetic ancestry proportion, which has been previously reported. Differences by age at diagnosis were apparent and concordant with what is known about pre- and post-menopausal-specific disease risk factors. Additional studies in Peru should be developed to further understand the main contributors to the specific age of onset and molecular disease subtypes in this population and develop population-appropriate predictive models for prevention.

Indexed as

breast cancergenetic ancestryHispanics/LatinasIndigenous Americantumor subtype

Identifiers

PMID36925912
PMCPMC10013058
OpenAlexW4321087215

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read116
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.